Skip to content
DraconiticResearch
Search Sources API
181,716 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BY-NC-NDMolecular and clinical oncology

Expression of vascular endothelial growth factor A with rich vascularization in conjunctival papilloma.

  • Mizuho Mitamura1
  • Satoru Kase1,2
  • Yuka Suimon1
  • Michiyuki Saito1
  • Ai Shimizu3
  • Susumu Ishida1
  1. 1Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060-8638, Japan.
  2. 2Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan.
  3. 3Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido 060-8648, Japan.
Read full textPDFDOICite

Abstract

Conjunctival papilloma (CP) is a benign epithelial neoplasm, characterized by a fibrovascular core and a high recurrence rate, highlighting the need to elucidate its pathogenesis and develop adjunctive therapies beyond excision. The present study aimed to immunohistochemically assess the expression of vascular endothelial growth factor A (VEGFA), an angiogenic factor, and related molecules in CP. A total of 16 CP tissue samples were included in the present study and immunohistochemical scoring was performed. The positive rates in a high-power field at a hotspot were determined using the hybrid cell count function of the BZ-X analyzer. The median positive rates of VEGFA, VEGF receptor 2 (VEGFR2), phosphorylated serine 59 αB-crystallin, CD34 and Ki-67 in primary CP cases (n=14) were 32.6, 29.3, 40.7, 2.4 and 11.6%, respectively. Because the number of recurrent cases (n=2) was limited, separate values for the recurrent subgroup are not emphasized, and no comparative conclusions were drawn. The correlation coefficient between the mean positive rates of VEGFA and CD34 in the same consecutive section was 0.63 (P=0.009). Furthermore, Masson's trichrome staining revealed a high number of arteries in the stem portion of pedunculated CP tissue. In conclusion, CP could be considered a highly vascularized tumor, and the expression of VEGFA and VEGFR2 in CP tumor cells suggests that these molecules may be involved in tumor proliferation and neovascularization.

Related

  1. Vascular normalization confers an endothelial immune suppressive gene expression profile.
    Liqun He, Michael Welsh
    Molecular oncologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCPMC
  2. Single cell RNA-seq analysis identifies junctional adhesion molecule two positive endothelial cells aggravate osteoarthritis by mediating vascular permeability and macrophage adhesion
    Yang Xing, Chengxin Li, Chao Wang +2
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  3. SELENOP-LRP8-mediated macrophage-endothelial cell interaction promotes breast cancer vascular invasion by inducing metabolic reprogramming in endothelial cells
    Haoran Wang, Yuan Song, Mengdi Ran +7
    Cellular and Molecular Life Sciences: CMLSPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMC
  4. LNP-mediated CRISPR gene editing of human vascular endothelial cells in 2D and 3D microfluidic cell culture systems
    Amalie Lykke Olsen, Camilla Blunk Vorsø Brandt, Rasmus Karred Larsen +11
    Molecular therapy. Nucleic acidsPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMCEurope PMCPMC
  5. Blood flow coordinates collective endothelial cell migration during vascular plexus formation and promotes angiogenic sprout regression via flt4
    Yan Chen, Aaron M. Savage, Zhen Jiang +5
    Development (Cambridge, England)Peer-reviewedCC BY 4.0Full text2 citedMolecular biology & gene regulationPMC

Cite

BibTeXRIS
BibTeX
@article{mitamura2026expression,
  title = {{Expression of vascular endothelial growth factor A with rich vascularization in conjunctival papilloma.}},
  author = {Mizuho Mitamura and Satoru Kase and Yuka Suimon and Michiyuki Saito and Ai Shimizu and Susumu Ishida},
  journal = {Molecular and clinical oncology},
  year = {2026},
  month = oct,
  doi = {10.3892/mco.2026.2978},
  url = {https://europepmc.org/article/MED/42923816},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Expression of vascular endothelial growth factor A with rich vascularization in conjunctival papilloma.
AU  - Mizuho Mitamura
AU  - Satoru Kase
AU  - Yuka Suimon
AU  - Michiyuki Saito
AU  - Ai Shimizu
AU  - Susumu Ishida
PY  - 2026
DA  - 2026/10/02
JO  - Molecular and clinical oncology
DO  - 10.3892/mco.2026.2978
UR  - https://europepmc.org/article/MED/42923816
AB  - Conjunctival papilloma (CP) is a benign epithelial neoplasm, characterized by a fibrovascular core and a high recurrence rate, highlighting the need to elucidate its pathogenesis and develop adjunctive therapies beyond excision. The present study aimed to immunohistochemically assess the expression of vascular endothelial growth factor A (VEGFA), an angiogenic factor, and related molecules in CP. A total of 16 CP tissue samples were included in the present study and immunohistochemical scoring was performed. The positive rates in a high-power field at a hotspot were determined using the hybrid cell count function of the BZ-X analyzer. The median positive rates of VEGFA, VEGF receptor 2 (VEGFR2), phosphorylated serine 59 αB-crystallin, CD34 and Ki-67 in primary CP cases (n=14) were 32.6, 29.3, 40.7, 2.4 and 11.6%, respectively. Because the number of recurrent cases (n=2) was limited, separate values for the recurrent subgroup are not emphasized, and no comparative conclusions were drawn. The correlation coefficient between the mean positive rates of VEGFA and CD34 in the same consecutive section was 0.63 (P=0.009). Furthermore, Masson's trichrome staining revealed a high number of arteries in the stem portion of pedunculated CP tissue. In conclusion, CP could be considered a highly vascularized tumor, and the expression of VEGFA and VEGFR2 in CP tumor cells suggests that these molecules may be involved in tumor proliferation and neovascularization.
SN  - 2049-9450
SN  - 2049-9469
ER  -